Publication: Effect of a short-term treatment with once-a-week medication of alendronate 70 Mg on bone turnover markers in postmenopausal women with osteoporosis
Submitted Date
Received Date
Accepted Date
Issued Date
2015-01-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
01252208
01252208
01252208
eISSN
DOI
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-84953342253
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.98, (2015), S70-S75
Citation
Likit Rugpolmuang, Saranatra Waikakul (2015). Effect of a short-term treatment with once-a-week medication of alendronate 70 Mg on bone turnover markers in postmenopausal women with osteoporosis. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36590.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effect of a short-term treatment with once-a-week medication of alendronate 70 Mg on bone turnover markers in postmenopausal women with osteoporosis
Alternative Title(s)
Author(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
© 2015, Medical Association of Thailand. All right reserved. Objective: The study was carried out to evaluate safety and efficacy of once-a-week medication of Kasparalendronate for inhibiting high bone turnover rate. Material and Method: Forty-nine postmenopausal osteoporotic participants were included in the study. This investigation was carried out as an open study. The participants received the drug every week for 12 weeks. Pain, drug side effects and bone turnover markers were evaluated at the 6thweek and 12thweek after the first visit. Results: None had significant complication and all could complete the trial. Thirteen participants, (26.3%), had minimal side effects, which the trial drug could be administered until the end of study. At the 12thweek follow-up, 42/49 participants (85.7%) had normal serum Beta-crosslab and 45/49 participants (91.8%) had normal serum N-MID osteocalcin. None showed any decrease in serum P1NP. All participants had slight reduction in serum alkaline phosphatase. Conclusion: The trial drug could inhibit high bone turnover in about 85% of post-menopausal participants within 12 weeks of drug administration and no severe side effect took place.